These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38954389)

  • 1. Estimating an EQ-5D-Y-3L Value Set for Brazil.
    Espirito Santo CM; Miyamoto GC; Santos VS; Ben ÂJ; Finch AP; Roudijk B; de Jesus-Moraleida FR; Stein AT; Santos M; Yamato TP
    Pharmacoeconomics; 2024 Sep; 42(9):1047-1063. PubMed ID: 38954389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating an EQ-5D-Y-3L Value Set for China.
    Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Value Set for the EQ-5D-Y-3L in the Netherlands.
    Roudijk B; Sajjad A; Essers B; Lipman S; Stalmeier P; Finch AP
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):193-203. PubMed ID: 36216977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EQ-5D-Y Value Set for Slovenia.
    Prevolnik Rupel V; Ogorevc M;
    Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L.
    Chemli J; Drira C; Felfel H; Roudijk B; Al Sayah F; Kouki M; Kooli A; Razgallah Khrouf M
    Qual Life Res; 2021 May; 30(5):1445-1455. PubMed ID: 33447958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
    Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
    Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
    Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
    Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An EQ-5D-Y-3L Value Set for Belgium.
    Dewilde S; Roudijk B; Tollenaar NH; Ramos-Goñi JM
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):169-180. PubMed ID: 36316544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
    Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
    Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents.
    Åström M; Rolfson O; Burström K
    Appl Health Econ Health Policy; 2022 May; 20(3):383-393. PubMed ID: 35083734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population health status based on the EQ-5D-Y-3L among adolescents in Sweden: Results by sociodemographic factors and self-reported comorbidity.
    Åström M; Persson C; Lindén-Boström M; Rolfson O; Burström K
    Qual Life Res; 2018 Nov; 27(11):2859-2871. PubMed ID: 30196340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
    Mott DJ; Shah KK; Ramos-Goñi JM; Devlin NJ; Rivero-Arias O
    Med Decis Making; 2021 Jul; 41(5):584-596. PubMed ID: 33733920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.